BIIB News and Headlines - Biogen Inc

GuruFocus Articles Total 277
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14

The stock of Biogen (NAS:BIIB, 30-year Financials) shows every sign of being modestly undervalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line,

0 Views    GF Value    2021-05-01 04:12
Even in face of pandemic, combined value of all pacts declined only slightly to $40 billion

In my April 27 discussion, I looked at the pharmaceutical companies that are most likely to pursue acquisitions this year, with activity forecasted to pick up after a down 2020. While the pandemic contributed to the slowdown in merger and acquisitions, licensing arrangements fared far better, coming in relatively flat at a total value of about $40 billion

Licensing is attractive to members of Big Pharma who need to fill gaps in their product line or get into entirely new therapeutic areas, but don't want to buy another company to acquire its assets. It's also usually a more

119 Views    Barry Cohen    2021-04-29 20:21
The company's Lomecel-B therapy could be a breakthrough in Alzheimer's disease

Stem cell research is an arm of biotechnology that has gained a lot of momentum over recent years. Many companies are focused on developing therapies using specialized cells from within the human body which possess unique regenerative qualities to repair and restore damaged tissues and organs.

One particularly interesting company is applying this kind of research to build therapies for Alzheimer's disease, aging, frailty and certain neurological disorders: Longeveron Inc. (LGVN). While most of the company's research is at the clinical stage, and it has only been generating revenue from grants as well as contract manufacturing so far, I believe

157 Views    Ishan Majumdar    2021-04-13 15:44
According to the baskets feature, these stocks could be worth further research

A few months ago, GuruFocus launched the "baskets" feature, which allows users to place stocks in one of four virtual baskets based on their level of interest:

  • Buying: You have invested money in the stock.
  • Considering: You have done research on the stock and you are considering purchasing shares.
  • Researching: You are doing research on the stock but are undecided about buying shares.
  • Not Interested: You have excluded the stock from consideration. Either you think the stock is too tough to understand or the stock is not worth considering at all.

Since the time of the feature's

3550 Views    Margaret Moran    2021-04-09 21:51
Ruling most impactful of several the agency will make in following months

Biogen Inc.'s (BIIB) management and shareholders are keeping their fingers crossed that the Food and Drug Administration rules favorably on the company's controversial Alzheimer's drug. The decision on what BioPharma Dive called "the most closely watched drug in all biotech" is expected by the first week in June.

A thumb's down by the agency is likely to send shockwaves throughout the industry and Biogen stock. An OK would make aducanumab the first marketed drug meant to slow the progression of Alzheimer's and, according to analysts, generate billions in annual sales for the company.

Naysayers note that the FDA's statisticians and

454 Views    Barry Cohen    2021-03-30 19:00

The stock of Biogen (NAS:BIIB, 30-year Financials) is believed to be modestly undervalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its

0 Views    GF Value    2021-03-28 15:12
Money came from venture capital, investors and Big Pharma

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

The numbers are eye-catching. In 2020, biotechs working in this space garnered nearly $20 billion in funding. That's 50% higher than the previous record of $13.5 billion in 2018 and a remarkable achievement coming in the face of Covid-19.

More than $5.5 billion of last year's investments flowed from venture capital financing for startups, the biggest being the $700 million raised by cell therapy developer Sana Biotechnology Inc.(SANA). That was

125 Views    Barry Cohen    2021-03-23 18:15
It's been a long time coming, but the great value comeback appears to be underway

It's been a long time coming, but the great value comeback appears to be underway.

The value school of investing, to which I adhere, seeks to find stocks selling for bargain prices compared to their intrinsic net worth. In the 30 years through 2009, value outperformed growth 19 times. That included a streak of seven years in a row from 2000 through 2006.

The growth school seeks stocks with rapidly rising earnings. It did great in the past decade, beating value seven times out of 10. Last year, growth stocks rose 36.9%, while value stocks gained 0.25%.

Those figures are

795 Views    John Dorfman    2021-03-22 13:58
Humana makes the list

According to the GuruFocus All-in-One Screener, a Premium feature, the following companies have high business predictability ratings and wide margins of safety as of March 16.


HCA Healthcare Inc. (HCA) has a 4.5-star business predictability rank and, according to the discounted cash flow calculator, an 11.88% margin of safety at an average price of $189.43 per share.

The health care provider has a market cap of $64.39 billion and an enterprise value of $97.97 billion. Over the past five years, its revenue and earnings per share have increased 5.90% and 16.90%.

Over the past 12 months, the stock

155 Views    Tiziano Frateschi    2021-03-16 21:37
Humana makes the list

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have grown their book value per share over the past decade through March 11.

Book value per share is calculated as total equity minus preferred stock, divided by shares outstanding. Theoretically, it is what shareholders will receive if a company is liquidated. Total equity is a balance sheet item and is equal to total assets minus total liabilities.

Since the book value per share may not reflect the company's true value, some investors check the tangible book value to confirm their investment ideas.

104 Views    Tiziano Frateschi    2021-03-11 17:53
Intel makes the list

According to the GuruFocus All-in-One Screener, a Premium feature, as of March 8, the following companies are trading below their Peter Lynch fair values with wide margins of safety and have had positive performances over the past 12 months.


Intel Corp. (INTC) was trading around $59.23 per share as of March 8. The Peter Lynch fair value is $84.62, which suggests the stock is undervalued with a 30% margin of safety. The stock has registered a 52-week increase of 1.68%.

The chipmaker has a market cap of $239 billion and an enterprise value of $251 billion.

899 Views    Tiziano Frateschi    2021-03-08 15:59
2020 was one of the most interesting years in our career. It turns out the best thing to do - as with almost any other year - was to stand pat

January 2021

To Our Officers and Investors:

Enclosed you will find our report on the 2020 performance of the Nintai Investments LLC Composite Portfolio managed by Nintai Investments LLC. Returns reflect performance since October 31, 2017 when the company began operations.

2020 returns

Overall, we were quite pleased with the Nintai model portfolio which is used as the basis for investment selection and asset allocation. At year-end, Nintai Investments LLC had $12,610,600 in assets under management (AUM). At the beginning of 2020, the company had $6,411,300 in AUM.

Our 2020 performance surpassed all three major indexes which we track. The

1438 Views    Thomas Macpherson    2021-01-28 19:44
Study shows analysts frequently overstate sales potential for new products

Investors considering pharmaceutical and biotechnology companies might want to factor in one important piece of data into their analysis: A high percentage of new products fail to reach sales forecasts made by industry analysts. This is according to a report from global management consulting firm L.E.K.

The report stated that about half of all products launched over the past 15 years have underperformed pre-launch consensus forecasts by more than 20%. While performance issues affected all disease areas, the biggest shortfall in Wall Street expectations was in infectious disease, immunology and cardiovascular diseases. And size does matter. On average, large pharma

223 Views    Barry Cohen    2021-01-21 23:08
These companies are trading below Peter Lynch value

As the Covid-19 vaccines from Pfizer (PFE), BioNTech (BNTX) and Moderna (MRNA) continue to be distributed throughout the U.S. and internationally to doctors, nurses, the elderly and other vulnerable populations, investors are looking to the health care industry to find value.

Even though the vaccine rollout has been slower than anticipated, drugstore chain CVS Health Corp. (CVS) reported on Wednesday that it is on track to complete the first round of vaccinations at nursing homes across the country by Jan. 25. The Trump administration partnered with CVS, Walgreens Boots Alliance Inc. (WBA) and other retail pharmacies in order to treat

532 Views    Sydnee Gatewood    2021-01-06 17:50
Biogen Inc tops the list

If you want to increase your likelihood of finding stocks that could beat the market, one method is to choose stocks that rank highly on the "Magic Formula" criteria.

The Magic Formula was created by Joel Greenblatt, a prominent value investor and author of one of the most successful books on investing, "The Little Book That Beats the Market." The Magic Formula makes a ranking of businesses, sorting them by specific characteristics that are described in the book. The two most significant criteria of the ranking are the earnings yield and the return on capital.

In Greenblatt's book, these two

268 Views    Alberto Abaterusso    2020-12-31 16:47
According to their GF Values, these fortress-like companies could represent value opportunities

Among the various preset screeners that GuruFocus offers to help users identify potential value opportunities, one of the more popular ones is the "High Quality" screener.

This screener looks for the stocks of companies that live up to a wide range of high expectations for profitability, growth and financial strength, such as a financial strength score of at least 6 out of 10, a profitability score of at least 7 out of 10, a five-year revenue growth rate of 5% or more and a five-year earnings per share without non-recurring items growth rate of 10% or more, among others.


883 Views    Margaret Moran    2020-12-16 20:51
Stocks that the GuruFocus consensus consider buying

As we look ahead to the Christmas holiday, GuruFocus users have placed several stocks on their Christmas wish lists. According to GuruFocus Baskets statistics, the six most-popular stocks in the "Considering" virtual basket as of Wednesday are Biogen Inc. (BIIB), Apple Inc. (AAPL), Intel Corp. (INTC), Bank of America Corp. (BAC), Facebook Inc. (FB) and Microsoft Corp. (MSFT).

The GuruFocus Baskets feature follows Berkshire Hathaway Inc. (BRK.A)(BRK.B) co-managers Warren Buffett (Trades, Portfolio) and Charlie Munger (Trades, Portfolio)'s theory of achieving higher returns by investing only within one's "circle of competence." GuruFocus

837 Views    James Li    2020-12-16 20:47
The firm reports 2 real-time trades in health care

PRIMECAP Management (Trades, Portfolio), an independent investment company based in Pasadena, California, disclosed this week a few Real-Time Picks dated Nov. 30.

According to the Real-Time Picks page, a Premium feature of GuruFocus, the firm disclosed the dissolvement of its Pfenex Inc. (PFNX) holding and a small increase to its Biogen Inc. (BIIB) position.

Firm dissolves Pfenex holding due to Ligand acquisition

San Diego, California-based Ligand Pharmaceuticals Inc. (LGND) announced in October that it completed the tender offer for all outstanding shares of Pfenex for $437.5 million in cash plus a non-transferrable contingent value right

197 Views    James Li    2020-12-11 20:31
Berkshire's equity portfolio contains several undervalued-predictable companies

As investors continue searching for Christmas bargains, five undervalued, predictable companies in Warren Buffett (Trades, Portfolio)'s third-quarter equity portfolio are Biogen Inc. (BIIB), The Kroger Co. (KR), Globe Life Inc. (GL), M&T Bank Corp. (MTB) and Bank of New York Mellon (BK) according to advanced current portfolio statistics, a Premium feature of GuruFocus.

U.S. markets remain significantly overvalued based on Buffett's market indicator

On Thursday, Buffett's favorite market indicator stood at 181.9%, close to an all-time high.


GuruFocus launched this week a new, modified Buffett Indicator that takes

1961 Views    James Li    2020-12-10 22:27
Biogen makes the list

According to the GuruFocus discounted cash flow calculator as of Dec. 9, the following companies have a high margin of safety and have grown their margins over a 10-year period.

Cia Paranaense De Energia

Cia Paranaense De Energia Copel's (ELP) net margin and operating margin have grown 9.02% and 13.76% per annum, respectively, over the past 10 years.


According to the DCF calculator, the stock is undervalued with a 51.42% margin of safety at $13.47 per share. The price-earnings ratio is 5.37. The share price has been as high as $18.15 and as

129 Views    Tiziano Frateschi    2020-12-09 15:09

Headlines Total 522
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

2021-05-09 $ 274.04 (%)
2021-05-06 $ 272.11 (0.2%)
2021-05-04 $ 271.02 (-1.56%)
2021-05-01 $ 267.33 (0.75%)
2021-04-28 $ 267.6 (0.08%)
2021-04-22 $ 259 (-4.02%)
2021-04-19 $ 269.05 (-0.47%)
2021-04-15 $ 270.44 (1.75%)
2021-04-13 $ 266.19 (1.29%)
2021-04-08 $ 265.73 (-0.85%)
2021-04-05 $ 277.88 (-0.3%)
2021-03-30 $ 276.01 (-0.03%)
2021-03-23 $ 267.21 (-1.88%)
2021-03-18 $ 262.27 (-0.71%)
2021-03-16 $ 259.92 (-0.08%)
2021-03-10 $ 262.61 (-1.46%)
2021-03-05 $ 270.71 (2.71%)
2021-03-04 $ 263.57 (-1.14%)
2021-03-02 $ 269.85 (-1.24%)
2021-03-01 $ 273.24 (0.13%)
2021-02-25 $ 277.26 (-1.94%)
2021-02-24 $ 282.74 (1.31%)
2021-02-23 $ 279.08 (-1.95%)
Is Biogen Stock a Buy? -
2021-02-18 $ 275.9 (-0.28%)
2021-02-12 $ 278.03 (-0.28%)
2021-02-11 $ 278.81 (1.39%)
2021-02-10 $ 275 (2.11%)
2021-02-09 $ 269.31 (0.14%)
2021-02-08 $ 268.93 (1.45%)
2021-02-05 $ 265.09 (-0.86%)
2021-02-04 $ 267.39 (1.57%)
2021-02-03 $ 263.25 (-5.21%)
2021-02-02 $ 277.72 (-0.27%)
2021-02-01 $ 278.46 (-1.47%)
2021-01-29 $ 282.61 (5.5%)
2021-01-27 $ 265.15 (-2.4%)
2021-01-19 $ 273.84 (-0.73%)
2021-01-15 $ 275.84 (-1.59%)
2021-01-14 $ 280.29 (5.11%)
2021-01-13 $ 266.67 (-0.27%)
2021-01-12 $ 267.39 (-0.05%)
2021-01-11 $ 267.52 (5.93%)
2021-01-09 $ 252.54 (0.84%)
2021-01-08 $ 252.54 (0.84%)
2021-01-06 $ 247.75 (0.55%)
2021-01-05 $ 246.39 (1.42%)
2020-12-31 $ 244.86 (0.53%)
2020-12-28 $ 244.15 (-1.9%)
2020-12-24 $ 248.89 (-0.92%)
2020-12-23 $ 251.2 (1.34%)
2020-12-22 $ 247.87 (-0.18%)
2020-12-21 $ 248.32 (-0.52%)
Total 522
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6